ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the
recent appointments of three executives with extensive
pharmaceutical industry experience in the areas of global quality,
medical affairs, and drug safety and pharmacovigilance.
Timothy Maines, Vice President, Quality,
ARIAD Pharmaceuticals, Inc. (Photo: Business Wire)
- Timothy Maines, Vice President,
Quality
- Yan Moore, M.D., Vice President,
Medical Affairs
- Piet A.M Vervaet, M.D., Vice President,
Drug Safety and Pharmacovigilance
“As we continue to strengthen our oncology business in the
United States and Europe, the recruitment of these three executives
to our management team demonstrates our commitment to building a
highly successful commercial oncology business,” stated Harvey J.
Berger, M.D., chairman and chief executive officer of ARIAD. “They
exemplify our core values and bring many years of highly relevant
experience to ARIAD in areas of fundamental importance to the
Company. I am pleased to welcome Tim, Yan and Piet to ARIAD and
look forward to their important contributions to our business.”
Timothy Maines leads the global quality function and has
put in place systems to ensure quality and compliance in clinical,
manufacturing and laboratory good practices. Mr. Maines brings over
twenty years of leadership experience in quality operations and
strategy to ARIAD.
Prior to joining ARIAD, Mr. Maines served as vice president,
quality at Omthera Pharmaceuticals, where he was responsible for
quality and technical GXP operations. He previously was vice
president, corporate quality assurance at MedImmune, LLC, where he
oversaw the quality assurance operations team at six GMP
manufacturing facilities. Mr. Maines also was vice president,
quality at GTC Biotherapeutics.
Mr. Maines has a B.S. degree in biology and microbiology from
Gannon University.
Yan Moore, M.D. leads global medical affairs and is
responsible for investigator-sponsored clinical-research
activities, publications, medical information, key therapeutic
leader engagement, medical affairs planning for ARIAD’s pipeline of
oncology products and in collaboration with others, for life-cycle
management of Iclusig® (ponatinib) and strategic planning for its
current and future clinical indications.
Prior to joining ARIAD, Dr. Moore served as associate vice
president, global medical affairs at Sanofi, where he was
responsible for global medical affairs, clinical development and
business opportunities for the company’s gastrointestinal and other
solid-tumor products. He previously was executive director,
oncology clinical development at GlaxoSmithKline and the cetuximab
development group director at Bristol-Myers Squibb (BMS). He also
was gastrointestinal cancer development lead for the oncology
portfolio. Before joining BMS, Dr. Moore headed the medical affairs
group at GPC Biotech, Inc. and was the global medical director at
GE Healthcare (Oncura, Inc.) for urology and genitourinary oncology
products.
Dr. Moore earned B.S. and M.D. degrees from the Sackler School
of Medicine in Tel Aviv, Israel. He completed his internship in
internal medicine at the Edith Wolfson Medical Center and a
residency program in obstetrics and gynecology. He received his
M.B.A. from the LeBow College of Business at Drexel University in
Philadelphia.
Piet A.M Vervaet, M.D. leads global safety and
pharmacovigilance and is responsible for safety surveillance, risk
identification and risk management for ARIAD’s marketed and
pipeline of oncology products, as well as proper risk
communications to patients, healthcare professionals and health
authorities. He also oversees, in collaboration with others,
regulatory compliance with safety legislation for the Company’s
products.
Prior to joining ARIAD, Dr. Vervaet served as vice president,
drug safety and pharmacovigilance at Onyx Pharmaceuticals, where he
was responsible for the strategic leadership and oversight for the
pharmacovigilance and drug-safety function and focused on proactive
and timely risk-benefit assessments of clinical data to
characterize the safety profiles of the company’s oncology
portfolio. He previously held therapeutic-area safety leadership
positions at AstraZeneca, where he oversaw the safety of products
in various therapeutic areas, including oncology, infectious
diseases, gastroenterology, and pulmonology. Before joining
AstraZeneca Dr. Vervaet held drug-safety positions in the U.S. and
Europe at Johnson and Johnson.
Dr. Vervaet earned his B.S. and M.D. degrees from the University
of Ghent in Belgium and completed residency programs at St.
Elisabeth Hospital in Sijsele/Damme (Belgium).
About ARIAD
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge,
Massachusetts and Lausanne, Switzerland, is an integrated global
oncology company focused on transforming the lives of cancer
patients with breakthrough medicines. ARIAD is working on new
medicines to advance the treatment of various forms of chronic and
acute leukemia, lung cancer and other difficult-to-treat cancers.
ARIAD utilizes computational and structural approaches to design
small-molecule drugs that overcome resistance to existing cancer
medicines. For additional information, visit
http://www.ariad.com or follow ARIAD on Twitter
(@ARIADPharm).
This press release contains “forward-looking statements”
including, but not limited to, statements regarding the progress
and results of the clinical development, risk identification and
risk management, regulatory processes, commercialization efforts or
commercial potential of ARIAD’s pipeline and marketed products.
Forward-looking statements are based on management's expectations
and are subject to certain factors, risks and uncertainties that
may cause actual results, outcome of events, timing and performance
to differ materially from those expressed or implied by such
statements. These risks and uncertainties include, but are not
limited to, preclinical data and early-stage clinical data that may
not be replicated in later-stage clinical studies, the costs
associated with our research, development, manufacturing and other
activities, the conduct, timing and results of pre-clinical and
clinical studies of our product candidates, the adequacy of our
capital resources and the availability of additional funding, and
other factors detailed in the Company's public filings with the
U.S. Securities and Exchange Commission. The information contained
in this press release is believed to be current as of the date of
original issue. The Company does not intend to update any of the
forward-looking statements after the date of this document to
conform these statements to actual results or to changes in the
Company's expectations, except as required by law.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20140623005256/en/
ARIAD Pharmaceuticals, Inc.For InvestorsKendra Adams,
617-503-7028Kendra.adams@ariad.comorFor U.S. Media,Liza
Heapes, 617-621-2315Liza.heapes@ariad.comorFor EU
MediaHeather Grant, 44 (0)207 32
1873hgrant@biosector2.co.uk
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Apr 2023 to Apr 2024